Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the first anti-CD38 therapy with VRd to significantly reduce disease progression or death by 40%.
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant.
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous stem cell transplant.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients.
How Is Multiple Myeloma (MM) Treated?
Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
Pharmabiz4m
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
Multiple myeloma gets new attention after Patti Scialfa, Bruce Springsteen's wife and bandmate, reveals diagnosis
The news that Patti Scialfa, Bruce Springsteen’s wife and bandmate, has multiple myeloma is bringing attention to the rare ...
Multiple myeloma, rare blood cancer: Bruce Springsteen's wife's diagnosis spotlights the illness
Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...
Patti Scialfa's Cancer Diagnosis: What To Know About Multiple Myeloma
Patti Scialfa, Bruce Springsteen’s Wife and E Street Bandmate, has been diagnosed with multiple myeloma. Find out more on ...
Pleasanton Weekly4d
Ray’s cancer story: Longtime Pleasanton resident opens up in ‘Me, Myself & My Multiple Myeloma’
"Cancer changes some things, of that there is no doubt. And, some things it takes away. Yet, at the same time, cancer can ...
6abc News12h
Blood cancer treatments advancing rapidly
Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.
oncnursingnews12d
Connecting Patients With Multiple Myeloma to Larger Institutions for CAR T-Cell Therapy
Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell ...
Cure Today4d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who ...